 12 PM / Updated 10 minutes ago BRIEF-Protalix Biotherapeutics Reports Positive Interim Data From Phase II Clinical Trial Of Oprx-106 Reuters Staff 1 Min Read 
Jan 2 (Reuters) - Protalix Biotherapeutics Inc: 
* PROTALIX BIOTHERAPEUTICS REPORTS POSITIVE INTERIM DATA FROM PHASE II CLINICAL TRIAL OF OPRX-106 IN PATIENTS WITH ULCERATIVE COLITIS 
* PROTALIX BIOTHERAPEUTICS - ‍TREATMENT WAS WELL TOLERATED AND MAJORITY OF ADVERSE EVENTS HAVE BEEN MILD TO MODERATE AND TRANSIENT IN NATURE IN STUDY​ 
* PROTALIX BIOTHERAPEUTICS - EXPECTS TO REPORT FULL RESULTS FROM PHASE II CLINICAL TRIAL OF OPRX-106 BY END OF Q1 2018  